#1Fourth Quarter Full-year 2022 Results Delivering on our purpose of using the power of leading-edge science to save and improve lives around the world Strong revenue growth MSD Strategic business development Scientific, commercial and operational success Worldwide Sales GAAP EPS Non-GAAP EPS1 Strong Q4 performance reflects continued business momentum $13.8B $1.18 $1.62 Full-year 2022 results reflect sustained revenue growth $59.3B $5.71 $7.48 2023 financial outlook $57.2B $5.86 $6.80 to to to $58.7B $6.01 $6.95 Full-year 2022 Sales KEYTRUDA (pembrolizumab) Injection 100 mg GARDASIL. [Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant] GARDASIL.9 Human Papillomavirus 9-valent Vaccine, Recombinant Lagevrio² molnupiravir MSD Animal Health $20.9B $6.9B $5.7B $5.5B "2022 was an exceptional year for MSD, which is a testament to the profound impact our medicines and vaccines are having on patients globally. I am extremely proud of what our talented and dedicated colleagues have accomplished scientifically, commercially and operationally. Our science-led strategy is working as we continue to build a sustainable engine that will drive innovation and generate long-term value for patients and shareholders well into the next decade." Rob Davis Chairman and Chief Executive Officer, MSD 1. A reconciliation of GAAP to non-GAAP EPS can be found in the company's earnings release. 2. LAGEVRIO is not approved, but is authorized for emergency use by the FDA.